Valneva SE
VALN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001836564
No open-market purchases or sales by Valneva SE insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $19.8M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Valneva SE changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 18 | 19 | +1 |
| Shares | 5.27M | 5.20M | −76.9K (−1.5%) |
| Value | $64.3M | $45.8M | −$18.5M (−28.8%) |
New holders (4)
Institutions that held Valneva SE at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 10,634 | $93.8K | 0.00% |
| China Universal Asset Management Co., Ltd. | 5,000 | $44.1K | 0.00% |
| Clearstead Advisors, LLC | 48 | $427 | 0.00% |
| Smartleaf Asset Management LLC | 43 | $359 | 0.00% |
Sold out (3)
Institutions that held Valneva SE at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Marshall Wace, LLP | 31,211 | $380.8K |
| VSM Wealth Advisory, LLC | 9,000 | $109.8K |
| Barclays PLC | 196 | $2.39K |